Switch theme
Sign up to access all valuation multiples
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
2020
69
LTM Revenue $0.1M
Last FY EBITDA -$89.2M
$298M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vigil Neuro has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vigil Neuro achieved revenue of n/a and an EBITDA of -$89.2M.
Vigil Neuro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vigil Neuro valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | -300% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$89.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$94.5M | XXX | -$89.7M | XXX | XXX | XXX |
| EBIT Margin | -65581% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$89.8M | XXX | -$84.3M | XXX | XXX | XXX |
| Net Margin | -62331% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Vigil Neuro's stock price is $8.
Vigil Neuro has current market cap of $372M, and EV of $298M.
See Vigil Neuro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $298M | $372M | XXX | XXX | XXX | XXX | $-1.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Vigil Neuro has market cap of $372M and EV of $298M.
Vigil Neuro's trades at n/a EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Vigil Neuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vigil Neuro has a P/E ratio of -4.1x.
See valuation multiples for Vigil Neuro and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $372M | XXX | $372M | XXX | XXX | XXX |
| EV (current) | $298M | XXX | $298M | XXX | XXX | XXX |
| EV/Revenue | 2064.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -3.1x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | -688.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.1x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVigil Neuro's last 12 month revenue growth is 2953%
Vigil Neuro's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Vigil Neuro's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vigil Neuro's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vigil Neuro and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2953% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vigil Neuro acquired XXX companies to date.
Last acquisition by Vigil Neuro was XXXXXXXX, XXXXX XXXXX XXXXXX . Vigil Neuro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vigil Neuro founded? | Vigil Neuro was founded in 2020. |
| Where is Vigil Neuro headquartered? | Vigil Neuro is headquartered in United States of America. |
| How many employees does Vigil Neuro have? | As of today, Vigil Neuro has 69 employees. |
| Who is the CEO of Vigil Neuro? | Vigil Neuro's CEO is Dr. Ivana Magovcevic-Liebisch, J.D.,PhD. |
| Is Vigil Neuro publicy listed? | Yes, Vigil Neuro is a public company listed on NAS. |
| What is the stock symbol of Vigil Neuro? | Vigil Neuro trades under VIGL ticker. |
| When did Vigil Neuro go public? | Vigil Neuro went public in 2022. |
| Who are competitors of Vigil Neuro? | Similar companies to Vigil Neuro include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vigil Neuro? | Vigil Neuro's current market cap is $372M |
| What is the current revenue of Vigil Neuro? | Vigil Neuro's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Vigil Neuro? | Vigil Neuro revenue growth (NTM/LTM) is 2953%. |
| What is the current EV/Revenue multiple of Vigil Neuro? | Current revenue multiple of Vigil Neuro is 2064.3x. |
| Is Vigil Neuro profitable? | Yes, Vigil Neuro is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
